HRP20150620T1 - Polipeptid za uporabu kod lijeäśenja infekcija denga virusom - Google Patents

Polipeptid za uporabu kod lijeäśenja infekcija denga virusom

Info

Publication number
HRP20150620T1
HRP20150620T1 HRP20150620TT HRP20150620T HRP20150620T1 HR P20150620 T1 HRP20150620 T1 HR P20150620T1 HR P20150620T T HRP20150620T T HR P20150620TT HR P20150620 T HRP20150620 T HR P20150620T HR P20150620 T1 HRP20150620 T1 HR P20150620T1
Authority
HR
Croatia
Prior art keywords
polypeptide
treatment
dengue virus
virus infections
infections
Prior art date
Application number
HRP20150620TT
Other languages
English (en)
Croatian (hr)
Inventor
Neil M. Bodie
Original Assignee
Trinity Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trinity Therapeutics, Inc. filed Critical Trinity Therapeutics, Inc.
Publication of HRP20150620T1 publication Critical patent/HRP20150620T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20150620TT 2008-07-18 2009-07-17 Polipeptid za uporabu kod lijeäśenja infekcija denga virusom HRP20150620T1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8194308P 2008-07-18 2008-07-18
EP09798797.8A EP2320924B1 (en) 2008-07-18 2009-07-17 A polypeptide for use in treating dengue virus infections
PCT/US2009/050966 WO2010009380A2 (en) 2008-07-18 2009-07-17 Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Publications (1)

Publication Number Publication Date
HRP20150620T1 true HRP20150620T1 (xx) 2015-09-25

Family

ID=41551029

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150620TT HRP20150620T1 (xx) 2008-07-18 2009-07-17 Polipeptid za uporabu kod lijeäśenja infekcija denga virusom

Country Status (13)

Country Link
US (1) US8815813B2 (enExample)
EP (1) EP2320924B1 (enExample)
JP (1) JP5806112B2 (enExample)
CN (1) CN102159231B (enExample)
AU (2) AU2009270805B2 (enExample)
BR (1) BRPI0915968B1 (enExample)
CA (1) CA2731218A1 (enExample)
HR (1) HRP20150620T1 (enExample)
IL (1) IL210717A (enExample)
MX (1) MX2011000647A (enExample)
MY (1) MY160699A (enExample)
SG (1) SG10201500597YA (enExample)
WO (1) WO2010009380A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086947A2 (en) * 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
EP3236986A4 (en) * 2014-12-22 2018-10-24 Middle Tennessee State University Methods for treating immune-mediated viral infections
SG11201709573YA (en) * 2015-05-20 2017-12-28 Univ Kagoshima Specific modification of antibody with igg-binding peptide
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
CN109071606A (zh) 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体
CN115804362A (zh) * 2023-02-08 2023-03-17 中国医学科学院医学生物学研究所 一种IFN-α/βR-/-小鼠抗体依赖性增强感染的注射液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US4383317A (en) 1980-10-30 1983-05-10 Bei Electronics, Inc. Shaft angle encoder having a circuit for synthesizing a skipped track output signal
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5693758A (en) 1987-11-19 1997-12-02 501 Research Corporation Limited Immunoglobulin E competitor
US5932483A (en) 1990-10-16 1999-08-03 Northwestern University Synthetic peptide and its uses
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6420127B1 (en) 1994-11-18 2002-07-16 Washington University Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
ITMI962628A1 (it) 1996-12-16 1998-06-16 Tecnogen Scpa Composizione farmaceutica
WO2000015214A1 (en) 1998-09-11 2000-03-23 Ilexus Pty Limited Fc RECEPTOR MODULATORS AND USES THEREOF
DE69926009D1 (de) 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2002038592A2 (de) 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6916904B2 (en) 2002-04-24 2005-07-12 Zolaris Biosciences, Llc Inhibition of immune complex formation
JP2005528918A (ja) 2002-06-07 2005-09-29 アースロン・リミテッド 自己免疫疾患用のFcγRIIaトランスジェニック動物モデル
AU2002953533A0 (en) 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
WO2005086947A2 (en) 2004-03-10 2005-09-22 Trinity Therapeutics, Inc. Method for inhibiting immune complex formation in a subjetc
EP1789067B8 (en) 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
EP1940436B1 (en) 2005-09-06 2013-12-04 Trinity Therapeutics, Inc. Methods for treating immune mediated neurological diseases
EP1960427B1 (en) 2005-12-13 2011-02-23 SuppreMol GmbH Multimeric fc receptor polypeptides
US20120021988A1 (en) 2007-08-14 2012-01-26 Bodie Neil M Methods for treating immune thrombocytopenia
WO2010009380A2 (en) 2008-07-18 2010-01-21 Trinity Therapeutics, Inc. Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome

Also Published As

Publication number Publication date
EP2320924B1 (en) 2015-03-11
CN102159231B (zh) 2016-06-15
CN102159231A (zh) 2011-08-17
AU2009270805B2 (en) 2016-11-03
SG10201500597YA (en) 2015-04-29
US20110218157A1 (en) 2011-09-08
JP5806112B2 (ja) 2015-11-10
EP2320924A4 (en) 2012-07-25
AU2009270805A1 (en) 2010-01-21
MX2011000647A (es) 2011-09-29
BRPI0915968B1 (pt) 2021-11-23
EP2320924A1 (en) 2011-05-18
BRPI0915968A2 (pt) 2020-08-18
JP2011528665A (ja) 2011-11-24
MY160699A (en) 2017-03-15
US8815813B2 (en) 2014-08-26
WO2010009380A2 (en) 2010-01-21
IL210717A (en) 2017-07-31
IL210717A0 (en) 2011-03-31
AU2017200760A1 (en) 2017-03-02
CA2731218A1 (en) 2010-01-21
HK1158066A1 (en) 2012-07-13
WO2010009380A9 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
PT2714036T (pt) Alifanos, ciclofanos, heterafanos, heterofanos, heteroheterafanos e metalocenos substituídos úteis no tratamento de infeções hcv
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
HUE036387T2 (hu) Pirrolopirimidin származékok vírusfertõzések kezelésében való felhasználásra
LTPA2017035I1 (lt) Gydymas afukozintu anti-CD20 antikūnu kartu su bendamustinu
BRPI1013642A2 (pt) derivado de triazina e composição farmacêutica compreendendo o mesmo
SI2935303T1 (sl) 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
HRP20180972T1 (hr) Kombinacija fenoksibenzamina i polimiksina e za liječenje mikrobnih infekcija
BRPI0912431A2 (pt) Combinações de substâncias ativas sinergísticas
EP2371333A4 (en) THIN CLEANER ARTICLE
BRPI0919150A2 (pt) aplicadores de fluxo de ar e métodos de tratamento relacionados
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0912768A2 (pt) vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
DK2310042T3 (da) Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
HRP20150620T1 (xx) Polipeptid za uporabu kod lijeäśenja infekcija denga virusom
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
HRP20160577T1 (hr) Liječenje osteoartritisa
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
BRPI0811572A2 (pt) Uso de compostos imunomoduladores no tratamento de doenças alérgicas
BRPI0822200A2 (pt) Composição pupicida e e larvicida